Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
| Author | |
|---|---|
| Abstract |
:
The oral AKT inhibitor ipatasertib is being investigated in cancers with a high prevalence of PI3K/AKT pathway activation, including triple-negative breast cancer. The LOTUS trial investigated the addition of ipatasertib to paclitaxel as first-line therapy for triple-negative breast cancer. |
| Year of Publication |
:
2017
|
| Journal |
:
The Lancet. Oncology
|
| Volume |
:
18
|
| Issue |
:
10
|
| Number of Pages |
:
1360-1372
|
| ISSN Number |
:
1470-2045
|
| URL |
:
https://linkinghub.elsevier.com/retrieve/pii/S1470-2045(17)30450-3
|
| DOI |
:
10.1016/S1470-2045(17)30450-3
|
| Short Title |
:
Lancet Oncol
|
| Download citation |
